https://ki.se RSS News Listing https://news.ki.se/thesis-on-clinically-reliable-ai-for-prostate-cancer-pathology Prostate cancer is one of the most common cancers in men globally. Diagnosing prostate cancer involves examining tissue samples under a microscope, a process that can be inconsistent and yield different results by different pathologists for the same sample, potentially affecting patient treatment. In some unclear cases, extra testing called immunohistochemistry (IHC) is used, but it adds cost, time, and lab work. Tue, 10 Jun 2025 08:42:53 +0200 https://news.ki.se/urine-test-could-reveal-prostate-cancer A newly published study involving researchers from Karolinska Institutet indicates that prostate cancer can be diagnosed at an early stage through a simple urine sample. With the aid of AI and extensive analyses of gene activity in tumours, they have identified new biomarkers of high diagnostic precision. Mon, 28 Apr 2025 18:00:12 +0200 https://news.ki.se/karin-holmsten-awarded-newly-established-scholarship-from-the-swedish-society-for-urological-oncology Karin Holmsten at Karolinska Institutet has been awarded Pfizer’s and the Swedish Society for Urological Oncology’s (SFUO) newly established research grant for oncologists in urology. The grant of 50,000 SEK was awarded on October 17th at SFUO’s annual meeting in Stockholm. Fri, 18 Oct 2024 07:49:19 +0200 https://news.ki.se/prostate-cancer-improving-detection-and-reducing-overtreatment Prostate cancer is the most common cancer among men in Sweden, with about 10,000 new cases diagnosed annually. Despite advancements in diagnostics and treatments, managing prostate cancer remains challenging due to its often silent progression and the complexities surrounding early detection. Tue, 08 Oct 2024 15:26:12 +0200 https://news.ki.se/wants-to-personalise-prostate-cancer-treatment Prostate cancer accounts for more male deaths in Sweden than any other form of cancer. However, how the disease progresses and how fatal it is depend on the type of tumour. Olof Akre hopes to find better prognostic indicators that will help to personalise treatment. Meet one of the new professors of Karolinska Institutet who will participate in this year's installation ceremony at Aula Medica on 3 October. Fri, 06 Sep 2024 09:00:11 +0200 https://news.ki.se/precision-therapy-for-metastatic-prostate-cancer-improves-survival Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy. However, the effect depends on which mutations the patient’s tumour carries. This is shown by results from the ProBio study, led by researchers at Karolinska Institutet in Sweden. The findings are published in Nature Medicine. Tue, 20 Aug 2024 11:00:16 +0200 https://news.ki.se/from-lab-to-hospital-new-test-launched-for-men-with-metastatic-prostate-cancer Routine diagnostic analyses of mutations in cell-free DNA in patients with metastatic prostate cancer are now possible for the first time in Sweden. The test has been developed by researchers at Karolinska Institutet, and Karolinska University Hospital is now offering the analysis to hospitals around the Nordic region, giving more patients with certain gene mutations access to the cancer treatment they need. Thu, 27 Apr 2023 13:37:24 +0200 https://news.ki.se/prostate-cancer-management-towards-personalization-with-ai-assisted-pathology-and-improved-active-surveillance Prostate cancer is a major global health concern and is the most common cancer-related cause of death in Sweden. Prostate cancer screening using PSA reduces prostate cancer mortality but also leads to significant overdiagnosis and overtreatment of low-risk cancers. The pathological evaluation of prostate biopsies determines the therapeutic course of treatment for prostate cancer patients. Tue, 24 Jan 2023 16:07:53 +0100 https://news.ki.se/prostate-cancer-testing-in-sweden-a-study-on-cost-and-effectiveness Prostate cancer constitutes an essential public health issue, as it is a major cause of male deaths. Early detection through an organised testing program with the prostate-specific antigen (PSA) test and systematic biopsy is not in place in most countries due to the risk of over-diagnosis and over-treatment of low-risk cancers. Now there are two proposed approaches to tackle this problem; magnetic resonance imaging (MRI) and the serum-based reflex test “Stockholm3”. Wed, 30 Nov 2022 16:06:23 +0100 https://news.ki.se/ki-researcher-receives-price-for-best-scientific-publication-in-prostate-cancer Associate Professor Tobias Nordström is awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022" for the Stockholm3-test, a blood test that in a better way can identify men who have an increased risk for prostate cancer. Mon, 04 Jul 2022 13:34:36 +0200 https://news.ki.se/taking-5-aris-for-bph-is-not-associated-with-increased-mortality-in-prostate-cancer 5-alpha-reductase inhibitors (5-ARIs), Finasteride and Dutasteride, are commonly used to treat lower urinary symptoms in older men with benign prostate hyperplasia. There has long been concern that these drugs may increase the risk of more aggressive forms of prostate cancer. In a new study recently published in JAMA Oncology, researchers at Karolinska Institutet found no increased risk of dying from prostate cancer for men treated with the drugs and lower risk with longer treatment duration. Tue, 31 May 2022 13:17:09 +0200 https://news.ki.se/new-blood-test-combined-with-image-based-prostate-cancer-screening-reduces-harms-and-costs The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study from Karolinska Institutet published in the journal European Urology. The results provide support for organised prostate cancer testing in Sweden, researchers say. Fri, 28 Jan 2022 09:00:09 +0100 https://news.ki.se/large-international-evaluation-shows-ai-accurately-diagnoses-prostate-cancer KI researchers have together with international collaborators completed a comprehensive international validation of artificial intelligence (AI) for diagnosing and grading prostate cancer. The study, published in Nature Medicine, shows that AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as pathologists. The results suggest AI systems are ready to be responsibly introduced as a complementary tool in prostate cancer care, researchers say. Thu, 13 Jan 2022 18:21:41 +0100 https://news.ki.se/henrik-gronberg-the-cancer-researcher-of-the-year-2022 The research committee at the Swedish Cancer Society has just named Henrik Grönberg “Cancer Researcher of the Year 2022” for his efforts in prostate cancer research. Henrik Grönberg’s research has contributed to earlier detection of prostate cancer and that unnecessary examinations can be avoided. Mon, 10 Jan 2022 15:33:13 +0100 https://news.ki.se/new-blood-test-improves-prostate-cancer-screening Researchers at Karolinska Institutet recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening. Now, the same research group has published a study in The Lancet Oncology, which shows that the addition of a novel blood test, the Stockholm3 test, can reduce the number of MRIs performed by a third while further preventing the detection of minor, low-risk tumours. Fri, 13 Aug 2021 00:30:05 +0200 https://news.ki.se/mri-can-cut-overdiagnoses-in-prostate-cancer-screening-by-half Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half. The results are presented today at the European Association of Urology Congress. Fri, 09 Jul 2021 10:15:04 +0200 https://news.ki.se/erb-suggested-as-additional-treatment-in-prostate-cancer The standard treatment for advanced metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). And even if this is efficient in the short term, 1/3 of PCa will become resistant to ADT and develop castration-resistant prostate cancer. A new study, by Karolinska Institutet and others, shows that estrogen receptor β (ERβ) agonists together with ADT could be considered useful in the treatment. Mon, 29 Mar 2021 09:34:51 +0200 https://news.ki.se/improved-survival-for-cancer-patients-in-a-large-nordic-comparison A comprehensive comparison of cancer survival between the Nordic countries shows improvements for all countries over time with previously observed differences attenuated. The reasons for these improvements are likely multifactorial. Previous studies comparing cancer survival between the Nordic countries have found marked differences, with a notably poorer survival in Danish patients. Mon, 19 Oct 2020 13:06:33 +0200 https://news.ki.se/artificial-intelligence-for-streamlining-prostate-cancer-diagnostics The objective of Peter's thesis is to develop and improve technologies for prostate cancer diagnostics and to acquire knowledge related to these technologies that directly translate to clinical utility. Mon, 27 Apr 2020 13:09:26 +0200 https://news.ki.se/ai-can-be-used-to-detect-and-grade-prostate-cancer Researchers at Karolinska Institutet have developed a method based on artificial intelligence for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to solve one of the bottlenecks in today’s prostate cancer histopathology by providing more accurate diagnosis and better treatment decisions. The study, presented in The Lancet Oncology, shows that the AI-system is as good at identifying and grading prostate cancer as world-leading uro-pathologists. Thu, 09 Jan 2020 00:30:00 +0100 https://news.ki.se/thesis-on-risk-prediction-in-prostate-cancer-diagnostics Title: Risk prediction in prostate cancer diagnostics : current challenges and improvements Mon, 16 Sep 2019 10:36:46 +0200 https://news.ki.se/a-new-method-to-select-the-right-treatment-for-advanced-prostate-cancer Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer. The results are published in the journal JAMA Oncology. The researchers envision that this discovery may eventually result in a test that contributes to a more personalised treatment of the disease. Fri, 24 May 2019 12:39:50 +0200 https://news.ki.se/combination-of-blood-test-and-imaging-improves-detection-of-prostate-cancer Mon, 09 Jul 2018 12:00:00 +0200 https://news.ki.se/swedish-prostate-cancer-test-to-be-introduced-in-europe Thu, 30 Mar 2017 15:04:58 +0200 https://news.ki.se/novel-molecular-processes-controlling-key-genes-in-prostate-cancer-uncovered Mon, 07 Mar 2016 17:15:00 +0100 https://news.ki.se/new-test-for-prostate-cancer-significantly-improves-screening Tue, 10 Nov 2015 07:00:00 +0100 https://news.ki.se/why-combined-therapies-increase-survival-in-prostate-cancer Thu, 05 Nov 2015 08:00:00 +0100 https://news.ki.se/physical-activity-improves-survival-for-men-with-localized-prostate-cancer Fri, 19 Dec 2014 09:00:00 +0100 https://news.ki.se/surgery-offers-better-survival-rate-in-prostate-cancer Thu, 27 Feb 2014 08:15:00 +0100 https://news.ki.se/men-with-prostate-cancer-more-likely-to-die-from-other-causes Fri, 27 Jul 2012 00:00:00 +0200